Which has stronger dopamine‑2 (D2) receptor antagonism, Latuda (lurasidone) or Abilify (aripiprazole)?

D2 Receptor Antagonism: Lurasidone vs Aripiprazole

Lurasidone (Latuda) has substantially stronger D2 receptor antagonism than aripiprazole (Abilify), because lurasidone is a full D2 antagonist while aripiprazole is only a partial D2 agonist—meaning aripiprazole actually stimulates D2 receptors at low dopamine states rather than blocking them. 1, 2, 3

Mechanism of Action Differences

Lurasidone's D2 Activity

• Lurasidone functions as a full antagonist at dopamine D2 receptors, providing complete blockade of these receptors regardless of the dopaminergic state 4, 5, 6
• This full antagonism is similar to most other second-generation antipsychotics like risperidone, olanzapine, and quetiapine 2, 5
• Lurasidone also has high affinity for serotonin 5-HT2A receptors (antagonist), 5-HT7 receptors (antagonist), and moderate affinity for 5-HT1A receptors (partial agonist) 5, 6, 7

Aripiprazole's D2 Activity

• Aripiprazole is mechanistically distinct as a dopamine D2 partial agonist, not an antagonist 1, 2, 3
• As a partial agonist, aripiprazole acts as an antagonist only when dopaminergic neurotransmission is excessive, but acts as an agonist (stimulating the receptor) when dopaminergic activity is low 3
• This "dopamine system stabilizer" mechanism attempts to normalize dopaminergic neurotransmission rather than simply blocking it 3
• Aripiprazole also has significant 5-HT1A partial agonism and 5-HT2A antagonism 2

Clinical Implications of These Differences

Extrapyramidal Symptoms (EPS)

• Lurasidone carries higher risk of EPS due to its full D2 antagonism, with akathisia being one of the most common adverse events, particularly at doses above 80 mg/day 4, 5
• The full D2 blockade in nigrostriatal pathways produces muscle rigidity and tremor through antagonism of D2 receptors 8
• Aripiprazole has reduced extrapyramidal side effects due to its partial agonist activity, which preserves some physiological dopamine function 1, 7

Metabolic Profile

• Both agents have favorable metabolic profiles compared to high-risk antipsychotics like clozapine and olanzapine 9, 2
• Lurasidone is associated with minimal weight gain and no clinically meaningful alterations in glucose or lipids 4, 6
• Aripiprazole has a superior metabolic profile with low risk of weight gain and minimal prolactin elevation, making it a first-line choice 1, 2

Prolactin Effects

• Lurasidone causes more prolactin elevation due to full D2 antagonism in the tuberoinfundibular pathway 10
• Aripiprazole causes minimal prolactin elevation because its partial agonist activity maintains some dopaminergic tone in this pathway 1, 2

Common Pitfall to Avoid

Do not assume that because both are "atypical" or "second-generation" antipsychotics they have similar D2 receptor activity—aripiprazole's partial agonist mechanism is fundamentally different from the full antagonism of lurasidone and most other antipsychotics 1, 2, 3. This distinction directly impacts side effect profiles, particularly regarding EPS, prolactin elevation, and the theoretical risk of neuroleptic malignant syndrome (which requires D2 antagonism) 8.